Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan G Ball

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of Clinical Psychopharmacology|January 15, 2009
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study designPierre-Michel Llorca, J Alexander Bodkin, Melissa Spann, et al.
International Psychogeriatrics|May 1, 2015
Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorderSusan G Ball, Sarah Lipsius, Rodrigo Escobar
The Journal of Clinical Psychiatry|January 27, 2005
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertralineSusan G Ball, Angela Kuhn, Delynda Wall, et al.
Chinese Medical Journal|November 18, 2011
Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in ChinaWen-Yuan Wu, Gang Wang, Susan G Ball, et al.
Lancet (London, England)|February 5, 2016
Ixekizumab for psoriasis--Authors' replyChristopher E M Griffiths, Kim A Papp, Susan G Ball, et al.
Journal of Clinical Psychopharmacology|March 28, 2015
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentSusan G Ball, Sarah Atkinson, JonDavid Sparks, et al.
Drugs in Context|January 17, 2014
Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentarySusan G Ball, Durisala Desaiah, Qi Zhang, et al.
Expert Review of Neurotherapeutics|February 13, 2009
Duloxetine in the treatment of generalized anxiety disorderSusan G Kornstein, James M Russell, Melissa E Spann, et al.
Dermatology and Therapy|June 8, 2023
The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia AreataNatasha Mesinkovska, Brittany Craiglow, Susan G Ball, et al.
Journal of Clinical Psychopharmacology|November 16, 2007
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trialsCharles M Beasley, Susan G Ball, Mary E Nilsson, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Clinical Psychopharmacology|January 15, 2009
A continuous responder analysis from a long-term trial of duloxetine treatment for generalized anxiety disorder: implications for the randomized withdrawal relapse prevention study designPierre-Michel Llorca, J Alexander Bodkin, Melissa Spann, et al.
International Psychogeriatrics|May 1, 2015
Validation of the geriatric anxiety inventory in a duloxetine clinical trial for elderly adults with generalized anxiety disorderSusan G Ball, Sarah Lipsius, Rodrigo Escobar
The Journal of Clinical Psychiatry|January 27, 2005
Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertralineSusan G Ball, Angela Kuhn, Delynda Wall, et al.
Chinese Medical Journal|November 18, 2011
Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in ChinaWen-Yuan Wu, Gang Wang, Susan G Ball, et al.
Lancet (London, England)|February 5, 2016
Ixekizumab for psoriasis--Authors' replyChristopher E M Griffiths, Kim A Papp, Susan G Ball, et al.
Journal of Clinical Psychopharmacology|March 28, 2015
Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentSusan G Ball, Sarah Atkinson, JonDavid Sparks, et al.
Drugs in Context|January 17, 2014
Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentarySusan G Ball, Durisala Desaiah, Qi Zhang, et al.
Expert Review of Neurotherapeutics|February 13, 2009
Duloxetine in the treatment of generalized anxiety disorderSusan G Kornstein, James M Russell, Melissa E Spann, et al.
Dermatology and Therapy|June 8, 2023
The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia AreataNatasha Mesinkovska, Brittany Craiglow, Susan G Ball, et al.
Journal of Clinical Psychopharmacology|November 16, 2007
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trialsCharles M Beasley, Susan G Ball, Mary E Nilsson, et al.
Pageof 3